Protease Nexin-1 (Serpine2) Matrix Metalloproteinase-9 (MMP-9) Matrix Metalloproteinase-2 (MMP-2) urokinase Plasminogen Activator (uPA) C6 glioma cell Cell invasion Protease Nexin-1 (PN-1) or Serpine2 is a physiological regulator of extracellular proteases as thrombin and urokinase (uPA) in the brain. Besides, PN-1 is also implicated in some human cancers and further identified as a substrate for Matrix Metalloproteinase (MMP)-9, a key enzyme in tumor invasiveness. Our aim was to study the role of PN-1 in the migration and invasive potential of glioma cells, using the rat C6 glioma cell line as stable clones transfected with pAVU6 + 27 vector expressing PN-1 short-hairpin RNA. We find that PN-1 knockdown enhanced the in vitro migration and invasiveness of C6 cells which also showed a strong gelatinolytic activity by in situ zymography. PN-1 silencing did not alter prothrombin whereas increased uPA, MMP-9 and MMP-2 expression levels and gelatinolytic activity in a conditioned medium from stable C6 cells. Selective inhibitors for MMP-9 (Inhibitor I), MMP-2 (Inhibitor III) or exogenous recombinant PN-1 added to the culture medium of C6 silenced cells restored either the migration and invasive ability or gelatinolytic activity thus validating the specificity of PN-1 silencing strategy. Phosphorylation levels of extracellular signal-related kinases (Erk1/2 and p38 MAPK) involved in MMP-9 and MMP-2 signaling were increased in PN-1 silenced cells. This study shows that PN-1 affects glioma cell migration and invasiveness through the regulation of uPA and MMP-9/2 expression levels which contribute to the degradation of extracellular matrix during tumor invasion.
Introduction
Protease Nexin-1 (PN-1) or Serpine2, is a 44 kDa serine protease inhibitor that belongs to the serpin super family [1] . While many serpins are found in plasma, PN-1 is present mainly in the extracellular matrix (ECM) and it is secreted by many different cell types, including fibroblasts [2] , myoblasts [3] , and vascular smooth muscle cells [4] . PN-1 inhibits the enzyme activity of extracellular proteases including thrombin, urokinase, urokinase Plasminogen Activator (uPA), tissue plasminogen activator (tPA) and plasmin [5, 6] by a suicide substrate mechanism mediated by the formation of a covalent complex with the target protease [7] . The serpin-protease complex binds to the low-density lipoprotein receptorrelated protein (LRP) that mediates its endocytosis and degradation, thus providing a localized mechanism for the inhibition and clearing of the protease from the extracellular environment [6] .
PN-1 was first identified as glia-derived nexin (GDN) [5] in the central nervous system (CNS) where it is primarily secreted by astrocytes [8] , glial [9] , and neuronal [10] cells. In the brain, PN-1 is the main physiological modulator of thrombin-mediated processes such as neurite outgrowth [11] , proteolytic damage and apoptosis in brain injury [12, 13] . Many evidences have shown that the balance between extra-cellular serine proteases and their cognate serpins play a role in many physiological [14] and pathological processes such as tissue remodeling [15] and cancer progression [16] .
Among PN-1 targets, thrombin is also known to regulate tumor cell invasion and metastasis [17] and uPA is critically involved in tumor angiogenesis and metastasis [18] . In addition, uPA controls cell migration through its ability to convert plasminogen into plasmin [19] and is involved in the maturation of other proteins, including Matrix Metalloproteinases (MMPs) and growth factors [20] . Also members of MMP family, especially MMP-2 and MMP-9, known as gelatinases A and B [21] , are critically involved in tumor angiogenesis and metastasis and also found overexpressed in malignant tissues [22] . In human tumors, the overexpression of MMP-9 and uPA have been associated with cancer progression [23] and poor prognosis in several cancer types [24] .
In the last years, the overexpression of PN-1 mRNA in some cancer cell lines and human cancers, including breast [25] and pancreatic tumors [26] , and oral squamous carcinomas [27] , has been correlated to metastatic process.
Further, in 2008, Xu et al. [28] reported that PN-1 is a substrate for MMP-9, thus suggesting a new function for this serpin, that may have a regulatory role on Matrix Metalloproteinase/s in the ECM [29] . Several authors explored the functional role of PN-1 in tumor biology and the relationship with MMP-9 and uPA, that are key enzymes in tissue remodeling and cancer progression by promoting the degradation of ECM components [30, 31] . However, controversial results have been reported in diverse tumor types and system models.
Up-regulation of PN-1 has been associated with the invasive potential of pancreatic cancer cells S2-028 in a nude mice xenograft model whereas no significant effects were observed using matrigel invasion and zymography assays [26] . In prostate cancer cells DU-145 and PC-3, PN-1 can affect the anti-invasive activity of the serine protease prostasin [32] .
Injections in nude mice of 4T1 mammary cancer cells, in which PN-1 had been silenced, did not affect primary tumor outgrowth whereas impaired metastatic potential that could be restored by coexpressing soluble MMP-9 [33] . Thus, these authors postulated a mechanism whereby PN-1, complexed with target proteases, binds the LRP-1 receptor thereby controlling MMP-9 expression and metastatic spread via Erk signaling.
In contrast, in 2010, Xu et al. [29] reported that prostate cancer cells, PC3-ML, overexpressing PN-1 or treated with MMP-9 shRNA, had reduced cell invasion in matrigel assay, through the inhibition of uPA activity. In addition, increased PN-1 amounts and inhibition of uPA activity were induced by the downregulation of MMP-9 in PC3-ML cells and in the tissue of MMP-9 deficient mice, consistent with PN-1 degradation by MMP-9 [28] . These authors indicated an anti-invasive function of PN-1 and showed a novel molecular pathway in which MMP-9 regulates uPA activity and tumor cell invasion through the cleavage of PN-1 [28] .
Gliomas are among the most common type of human primary brain tumors with an infaust prognosis [34] . Since no studies are available on PN-1 functions in glioma tumors, this study was designed to investigate the role of PN-1 on migration and invasion ability on cells derived from rat glioma. The rat C6 glioma cell line [35] was chosen as an in vitro model system because these cells maintain many characteristics of "glioblastoma multiforme" (GBM) [36] and constitutively secrete PN-1 [9] . We used a vector-based (pAVU6 + 27) [37] RNA interference (RNAi) approach [38] to silence PN-1 expression in C6 cells. Selected clones were tested for migration and invasion ability using migration and matrigel invasion assays and the results were compared to control unsilenced cells, transfected with the empty vector. We have analyzed the effects of PN-1 silencing on expression levels of its target proteases, such as thrombin, uPA and MMP-9. Moreover, our study also focused on the gelatinase A, MMP-2, which is the metalloproteinase closely related to MMP-9 for structure and biological functions. Thrombin, uPA, MMP-9 and MMP-2 protein and mRNA expression levels were evaluated either by western blotting or semiquantitative RT-PCR analysis, respectively. MMP-9, MMP-2 and uPA enzyme activities were assessed by SDS-PAGE zymography analysis. Our results demonstrated a correlation between the enhancement of migration and invasion ability and up-regulation of uPA, MMP-9 and MMP-2 expression levels triggered by PN-1 silencing in C6 glioma cells. In addition, we determined the phosphorylation levels of the extracellular signal-related kinases, Erk1/2 and p38 MAPK [39] , known to be implicated in the migration and invasion ability of various cell types, through the activation of plasminogen activators (PAs) and MMPs [33, 40, 41] .
Materials and methods

Construction of pAVU6+27-siPN-1 expression vectors
Three siRNA sequences targeting rat PN-1 were selected using the Ambion and Genescript web-based (www.ambion.com; www. genescript.com) criteria. The selection was performed by identifying target sites along the open reading frame of rat PN-1 gene sequence (NCBI, Reference Sequence: NM_019197.1; Supplementary Fig. 1A ). The RNAi sequences were the following: D31: 5′-AGGAACCAUGAAUUGGCAU-3′, spanning nucleotides 118 to 136; 2G: 5′-CCACAGUGACUUUAUCCUC-3′, spanning nucleotides 156 to 174; A7: 5′-GUCACUCGAGGAACUAGGC-3′ spanning nucleotides 199 to 216.
The corresponding DNA sequences were chemically synthesized as a couple of complementary oligos (CEINGE, Naples, Italy) containing also a SalI at the 5′ end and XbaI at the 3′ end ( Supplementary Fig. 1B ) restriction sites, used for cloning in the pAVU6 + 27 vector [37] that contains one U6 promoter cassette and the first 27 nucleotides of human U6 RNA ( Supplementary Fig. 2A ). The RNAi sequences and the secondary structure of hairpin oligos are reported in Supplementary  Fig. 2B .
For the cloning procedure, the two oligos of which above were incubated at 95°C for 30 min with annealing buffer (10 mM TrisHCl, pH 7.8, 100 mM NaCl), gradually cooled to room temperature to anneal shDNAs. These were then inserted into the SalI and XbaI restriction sites of pAVU6 + 27 vector previously digested with these endonucleases.
The resulting shRNA expression vectors, named pAVU6 + PN1-D31, pAVU6 + PN1-2G and pAVU6 + PN1-A7 were transformed into Escherichia coli strain DH5α. Transformants were grown overnight and purified plasmids were first subjected to 1.5% agarose gel electrophoresis for restriction analysis prior DNA sequence determination.
Cell culture, DNA transfection and generation of C6 stable cell clones
The C6 rat glioblastoma cell line [35] (American Type Culture Collection, ATCC, CCL-107) was cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1.5 mM L-glutamine, 50 IU/ml penicillin and 50 μg/ml streptomycin. Human glioblastoma (A 172), glioblastoma-astrocytoma (U-87 MG, U-373 MG) and astrocytoma (SW-1088) cell lines were provided by the cell culture facility and biobank of CEINGE-Biotecnologie Avanzate, Naples, Italy. A 172 cells were cultured in DMEM supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 50 IU/ml penicillin and 50 μg/ml streptomycin; U-87 MG and U-373 MG cells in Eagle's minimal essential medium (EMEM) with 10% FBS, 2 mM L-glutamine; SW-1088 cells were grown in Leibovitz's L-15 medium with 10% FBS, 2 mM Lglutamine. The cells were maintained at 37°C in a 5% CO 2 atmosphere and sub-confluent cultures (70-80%) were splitted 1:3 to 1:6 twice a week by a 0.25% trypsin solution and then seeded at appropriate cell density with a culture medium.
For DNA transfection, C6 cells were seeded subconfluent on 60-mm plates; 24 h after plating, cotransfection was carried out using 4 μg of each pAVU6 + PN1-I plasmid and 1 μg of pTK-Hygro plasmid (cat. n. 631750, Clontech, Italy) using the calcium phosphate precipitation technique [42] ; 16 h after transfection, precipitates were washed off and, to select stable transfected cell clones, a fresh medium containing the lowest lethal concentration of Hygromycin B (0.5 mg/ml, cat. n. sc-29067, Santa Cruz, Italy) was added. Cells transfected with empty pAVU6+27 (4 μg) and pTK-Hygro (1 μg) vectors were used to generate stable clones used as unsilenced control (Ctrl cells); untrasfected C6 cells were used as basal control. For each transfected plasmid, at least 8 stable cell clones were isolated and further amplified. After 24, 48 and 72 h following depletion of the antibiotic, cells were harvested and the culture media were collected and assayed for the detection of PN-1 expression level by western blotting analysis. Stable clones with the lower level of protein secretion were chosen for further characterization. For rescue experiments, cells were exposed to a serum-free medium containing exogenous recombinant PN-1 [43] added to a final concentration of 200 or 500 ng/ml for 48 h.
For the preparation of a conditioned medium, subconfluent cells were grown in 100-mm plates in DMEM supplemented with 10% FBS until confluency, washed with phosphate-buffered saline (PBS, pH 7.4) three times and then incubated in the serum-free medium. After 48 h, the medium was collected, centrifuged at 6000 ×g for 20 min to remove cells and debris, and concentrated approximately 20-fold by centrifugation at 5000 ×g using Ultra-4, PLGC Ultracel-PL Membrane, 10 kDa cut-off (cat. n. UFC801024, Merck Millipore, Italy) at 4°C. The volume of the concentrated medium was measured and stored in aliquots at − 80°C until use. Aliquots of the concentrated medium corresponding to identical amount of cell proteins (100 μg) were analyzed by western blotting and gelatin zymography analysis.
Migration and matrigel invasion assays
Cell migration assay was performed using BD Falcon™ Cell Culture Inserts (cat. n. 353097, BD Bioscience, Bedford, MA; 8 μm) in 24-well culture plates. Cell invasion assay was performed by BD Falcon BioCoat Matrigel Invasion Chambers (cat. n. 354480, BD Bioscience, Bedford MA; 8 μm). The cell culture inserts were rehydrated and prepared as described in the manufacturer's instructions. Briefly, 2 · 10 4 cells in 0.5 ml of DMEM with 0.5% FBS were seeded in the upper chamber and 750 μl medium with 5% FBS was placed in the lower chamber. After 24 h, non-migrating cells in the upper chamber were removed with the cotton swab and the cells at the bottom of the filters were fixed and stained with Diff-Quick kit (cat. n. B4132-1A, Becton-Dickinson). After two washes with water, the inserts were allowed to air dry and phase-contrast images were captured using a Zeiss Axiovert 40 CFL inverted microscope (Carl Zeiss, Milan, Italy) (LD A-Plan 20×/0.30 Ph 1 objective). The microscope was equipped with a 12.1-megapixel CCD digital video camera (Canon, PowerShot G9, Italy) with a digital image software (Remote Capture DC, Canon). To assess cell migration and invasion ability, the total number of cells was determined by cell counting in five fields randomly selected per membrane. To determine the role of MMP-9 and MMP-2 in effects induced by PN-1 down-regulation, the selective MMP-9 (2-(N-benzyl-4-methoxyphenylsulfonamido)-5-((diethylamino)methyl)-hydroxy-3-methylbenzamide); MMP-9 Inhibitor I) [29, 44, 45] 
Reverse transcription (RT), quantitative real-time polymerase chain reaction and RT-PCR analyses
Total RNA was purified from C6 cells and stable clones using a commercial kit (RNeasy mini kit, Qiagen, Valencia, CA, USA) including treatment with DNase I to prevent genomic DNA contamination (Turbo DNA-free Kit; cat. n. AM1907; Ambion, Foster City, CA) according to the manufacturer's instructions. The concentration and purity of RNA were determined spectrophotometrically by reading the absorbance at 260 and 280 nm. Total RNA (2 μg) was reverse-transcribed to cDNA by using the SuperScript III First-Strand Synthesis System (cat. n. 18080-051; Invitrogen, Italy), according to the manufacturer's protocol. Three replicates were used for each sample.
For quantitative real-time PCR (qPCR) analysis, the Rn 01400467_m1 Assays-on-Demand Gene expression (Applied Biosystems, Foster City, CA, USA) was used, which contains a primer pair between exon 4 and exon 5 (amplicon of 79 bp) and a TaqMan probe centered on nucleotide 809 (RefSeq NM_019197.1) conjugated to the 5′ with 6-FAM fluorochrome and to the 3′ with the MGB-NFQ. The housekeeping gene β-actin, used as endogenous control, was analyzed with the Rn 00667869_m1 Assays-on-Demand Gene expression (Applied Biosystems, Foster City, CA, USA), which contains a primer pair between exon 4 and exon 5 (amplicon of 91 bp) and a TaqMan probe centered on nucleotide 888 (RefSeq NM_031144.2) conjugated to the 5′ with 6-FAM fluorochrome and to the 3′ with the MGB-NFQ.
A
Real-time PCR assays were carried out, in triplicate, for each sample in a total reaction volume of 20 μl, which contained 12.5 μl of TaqMan OneStep RT-PCR Master Mix, 1 μl of 20× Assays-onDemand Gene expression Assay Mix, 0.8 μl of a mixture of Recombinant reverse transcription of moloney murine leukemia virus (0.25 U final concentration) and RNase inhibitor (0.4 U/μl final concentration), 5 μl of total RNA template (10-100 ng) from each cell culture, and 5.7 μl of RNase free water.
PCR conditions were as follows: cycling was preceded by heating at 48°C for 30 min for RT, followed by a step at 95°C for 10 min, then 40 cycles at 95°C for 15 s, 60°C for 60 s and 72°C for 20 s. The cycle threshold values were used to calculate the normalized expression of PN-1 against β-actin. Real-time PCR was performed in the ABI Prism 7500 Sequence Detection System using a SYBR Green detection system (cat. n. 170-8880; Bio-Rad Laboratories. Italy). Relative quantification Ctrl A7.6 D31.6 Fig. 3 . Effects of PN-1 silencing on thrombin and uPA expression levels. Sub-confluent un-silenced, A7.6 and D31.6 cells were switched to the serum-free medium for 48 h and then harvested for the preparation of protein extracts or purification of total RNA. Conditioned media were collected and concentrated by ultrafiltration, and volumes corresponding to 100 μg of cellular proteins were loaded onto 12% SDS-PAGE followed by thrombin (A) or uPA (B) immunoblotting analysis or analyzed under nonreducing conditions through a 12% SDS-polyacrylamide gel co-polymerized with casein (0.2%) and bovine plasminogen (3.75 mU/ml) for casein zymography (C). Semiquantitative RT-PCR analysis of uPA expression levels on total RNA isolated from the unsilenced, A7.6 and D31. was performed using the ABI 7500 SDS Software and data were analyzed according to Pfaffl [47] . By identifying the threshold cycle (C T ) for the expression of mRNA, the ΔC T for PN-1 was calculated and compared to vector transfected control cells. The ΔC T was converted into a ratio (target A/target B = 2 
In situ zymography
Glass coverslips (12 mm) were coated with fluorescein isothiocyanate (FITC)-gelatin (cat. n. D-12054, DQ™ gelatin, Molecular Probe) for in situ zymography (ISZ) as reported [52] . 5 · 10 4 cells seeded onto FITC-gelatin coated glass coverslips were kept in DMEM with 10% FBS for 24 h; after the incubation, the coverslips were washed three times with PBS and serum-free DMEM was added to allow gelatin degradation. Rescue experiments were performed in the presence of exogenous recombinant PN-1 [43] (200 or 500 ng/ml) for 6 or 24 h. Finally, the cells were fixed in 4% paraformaldehyde mounted on slides with Vectashield® containing 1.5 μg/ml 4′6-diamidino-2-phenylindole (DAPI) (VECTOR Laboratories) to visualize the nuclei. Images were captured by using a Zeiss LSM 510 meta confocal microscope equipped with an oil immersion plan Apochromat 63 × objective 1.4 NA, using the following settings: green channel for detecting FITC, excitation 488 nm argon laser, emission bandpass filter 505-550 nm; blue channel for detecting DAPI, excitation 405 nm blue diode laser, and emission bandpass 420-480 nm.
Western blotting analysis
Whole protein extracts were prepared by lysing cells in 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1% Igepal, 1 × protease inhibitor (cat. n. 11836153001, Roche Applied Science, Italy) and phosphatase inhibitor cocktail (cat. n. 524627, Calbiochem, Italy). Protein concentration was determined by the Bradford protein assay [53] using bovine serum albumin as standard; identical amounts of proteins (30 μg) were subjected to 12% SDS-PAGE performed as described by Laemmli [54] .
For protein analysis on the conditioned medium, appropriate volumes of concentrated samples corresponding to 100 μg total proteins were loaded onto 12% or 7% reducing SDS-PAGE. After electrophoresis, proteins were transferred to a nitrocellulose membrane (BA85; Schleincher & Schull) and then incubated with the specific primary antibody. In particular, the following antibodies were used: After incubation with the appropriate anti-mouse, anti-rabbit (1:10 000, cat. n. 31430 and cat. n. 31460, respectively, Pierce, Thermo Scientific, Italy) or anti-goat (1:5000, cat. n. sc-2020, Santa Cruz Biotechnology, Italy) peroxidase-linked secondary antibody, detection was achieved using Enhanced Chemiluminescence (ECL) kit (cat. n. RPN 2209, GE Healthcare, Italy). Densitometric analysis was performed using the free image-processing software ImageJ, version 1.47 (http:// rsb.info.nih.gov/ij/).
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Gelatin and casein gel zymography
Gelatinolytic activity in the cell conditioned medium was detected by SDS-PAGE zymography. Samples were analyzed under nonreducing conditions without boiling, through a 7% SDS-polyacrylamide gel co-polymerized in the presence of gelatin (1 mg/ml, cat. n. G1890, Sigma-Aldrich, Italy) [56] for gelatinolytic zymography or through a 12% SDS-polyacrylamide co-polymerized with casein (0.2%, cat. n. C3400 Sigma-Aldrich, Italy) and bovine plasminogen (3.75 mU/ml, cat. n. P9156, Sigma-Aldrich, Italy) for casein zymography [57] . After the electrophoresis run, carried out at 35 mA for 90-120 min at 4°C, the proteins in the gels were renatured in a 2.5% Triton X-100 solution for 1 h. The gels were then incubated with 50 mM Tris-HCl, pH 7.5, 200 mM NaCl, 5 mM CaCl 2 and 5 μM ZnCl 2 at 37°C for 48 h, which allows substrate degradation. Finally, the gels were fixed in 30% methanol, 10% acetic acid for 30 min., stained with 0.5% Coomassie Brillant Blue R-250. Proteolytic bands were visualized by destaining with 50% methanol and 5% acetic acid. Gelatin zymography was also performed in the presence of MMP-9 Inhibitor I (100 μM) [28] or MMP-2 Inhibitor III (200 nM) [46] that were added during the development of the gelatin gels.
MMPs activity vs
Statistical analysis
Statistical significance of samples against control or untreated cells was determined by One-way analysis of Variance (ANOVA), followed by the Dunnett's test. Each value represents the mean ± SEM of at least three independent experiments performed in triplicate ( ⁎ p b 0.05; § p b 0.01; # p b 0.001).
Results
Construction of PN-1 shRNA expression plasmids
Recombinant pAVU6 + 27 plasmids encoding short hairpin RNA (shRNA) were constructed to stably suppress PN-1 levels in C6 cells. Three putative target sequences for siRNAs (D31, 2G and A7) were identified in the upstream region of PN-1 cDNA by bioinformatic analysis (Supplementary Fig. 1A ). The corresponding nucleotide sequences ( Supplementary Fig. 1B ) were used to generate pairs of synthetic oligonucleotides, containing appropriate restriction sites for successive vector cloning. The pAVU6 + 27 vector, containing one U6 RNA-polymerase III promoter cassette and the first 27 nucleotides of human U6 RNA (Supplementary Fig. 2A ), was digested with SalI and XbaI restriction enzymes, to generate compatible ends for cloning. In the resulting plasmids, the transcript was expected to fold into a secondary structure to form a suitable target for anti-PN-1 shRNA, composed by two aligned 19-nucleotide regions in an inverted orientation separated by a 9-nucleotide loop ( Supplementary Fig. 2B ). The shRNA expression vectors, namely pAVU6 + 27-PN-1-shD31 (pD31), pAVU6 + 27-PN-1-sh2G (p2G) and pAVU6 + 27-PN-1-shA7 (pA7) were subjected to DNA sequence analysis and tested for their ability to knock-down PN-1 expression.
PN-1 silencing by shRNA in C6 cells
To study the role of PN-1 in the migration and invasion capability of glioma cells, we have first analyzed the expression levels of PN-1 either on the serum-free cell conditioned medium (Fig. 1A, B) or protein cell extracts ( Supplementary Fig. 3A ) from rat (C6) and human glioblastoma-astrocytoma (A 172, U-87 MG, SW-1088 and U-373 MG). Expression level of secreted PN-1 was higher in rat C6 cells in comparison with the other human cell lines analyzed; vice versa, no significant difference was observed in the cytosolic PN-1 espression levels ( Supplementary Fig. 3A ) among the cell lines analyzed. Therefore, C6 cells were used to silence PN-1 expression by the generation of stable cell clones co-transfecting recombinant shRNA PN-1 expression vectors (pA7, p2G or pD31) and pTK-Hygro plasmid. A control cell line was generated by transfection with pAVU6 + 27 empty vector (control, Ctrl cells). The effects of shRNA on PN-1 expression in stable cell clones were evaluated by monitoring both protein and mRNA levels by means of western blotting (Fig. 1C,  D and Supplementary Fig. 3B ) and RT-qPCR analysis (Fig. 1E) , respectively. In particular, compared to the control clone, secreted PN-1 protein levels (Fig. 1C, D) were markedly reduced (~5 fold) in the conditioned medium from D31.6 and 2G.2 cells. Moreover, in 2G.3 cells only a moderate decrease of the serpin was observed (~2 fold), whereas in A7.6 cells only a minimal decrease (~1.5 fold) was found. It has to be pointed out that the transfection with the empty pAVU6+27 vector (control clone) had no effect on endogenous PN-1 levels, that were similar to those found in untransfected C6 cells. Furthermore, PN-1 mRNA levels correlated well with the protein expression in each cell line (Fig. 1E) . These results indicate that the RNA interference approach silenced PN-1 expression, both at protein and mRNA levels in C6 cells, although with different efficiencies among the shRNAs analyzed. Finally, the two clones D31.6 and A7.6, representing the more or the less effective at PN-1 silencing, respectively, were selected for subsequent cellular and biochemical studies.
MMPs activity vs
PN-1 silencing enhances migration and invasive activity in C6 glioma cells
To determine the role of PN-1 in glioma cell migration and invasiveness, Ctrl, A7.6 and D31.6 cells were subjected to the Boyden chamber migration and matrigel invasion assays. The cells were plated in the upper chamber of cell culture inserts uncoated or pre-coated with matrigel and after 24 h incubation, the cells that had migrated or invaded through the membranes were fixed, stained and observed by phase-contrast microscopy ( Fig. 2A) . D31.6 cells exhibited a significant increase (p b 0.001) in both migration (~2.5-fold) and invasive (~3-fold) capabilities, compared to unsilenced cells (Fig. 2B) . Vice versa, the migration and invasive ability of A7.6 cells was only slightly higher (~1.3-fold) than unsilenced cells. These results, besides confirming those obtained with the PN-1 silencing reported above, indicate that the serpin is involved in the migration and invasive ability of glioma cells.
Effects of PN-1 silencing on thrombin and urokinase-type plasminogen activator expression levels in C6 cells
Among PN-1 serine protease targets, thrombin and uPA are also involved in tissue remodeling and tumor invasion [58, 59] . The effects of PN-1 silencing on thrombin expression levels were analyzed by immunoblotting analysis on the conditioned medium from Ctrl, A7.6 and D31.6 cells (Fig. 3A) . A polyclonal antibody against prothrombin only recognized a single immunoreactive band, at about 72 kDa, corresponding to the inactive zymogen and no signal corresponding to the enzymatically active thrombin fragment (34 kDa) [60] was detected. In addition, prothrombin expression levels were not altered by PN-1 silencing.
We also assessed uPA protein levels, enzyme activity and mRNA expression on A7.6 and D31.6 cells. western blotting (Fig. 3B) showed that D31.6 cells had a significant increase (~2.5-fold) of uPA protein levels, whereas A7.6 cells had only minimal variation with respect to unsilenced cells. The observed increase of uPA protein levels correlated with a higher enzyme activity (~4.3-fold) in comparison to A7.6 and unsilenced cells, as evaluated by casein zymography (Fig. 3C) . Finally, semiquantitative RT-PCR analysis (Fig. 3D) demonstrated only a moderate increase in uPA mRNA levels in D31.6 and A7.6 cells compared to unsilenced cells. These data indicate that PN-1 downregulation did not alter prothrombin expression levels whereas led to a significant increase of uPA protein expression levels and activity in C6 glioma cells.
PN-1 silencing leads to an increase of MMP-9 and MMP-2 levels and gelatinase activity in C6 cells
We also evaluated whether the enhancement in cell migration and invasive ability involves MMP activity in PN-1 silenced C6 cells. To this aim, we used in situ zymography (ISZ) that allows the localization of cell gelatinase activity (Fig. 4) . A stronger gelatinolytic activity (~2. rPN-1 (C, D) . After 48 h, cells were re-suspended in lysis buffer and 40 μg of total cell proteins were loaded onto 12% SDS-PAGE followed by immunoblotting analysis (A, C) to evaluate phospho-Thr202/Tyr204 form of Erk1/2 and Erk1/2 total protein; phospho-Thr180/Tyr182 form of p38 MAPK and p38 MAPK total protein expression levels. GAPDH was used as protein loading control. Signals were revealed by immunostaining and ECL detection (B, D). Densitometric analysis showing fold change in expression levels of phospho-Erk1 (gray bar), phospho-Erk2 (black bar) and phospho-p38 (empty bar) vs the respective total protein expression level. Prior to fold calculation, signals were normalized vs GAPDH expression levels in individual samples. Data were reported as relative to control cells, set as 1. Each bar represents the mean ± SEM (n = 3). Bars statistically different from control ( ⁎ p b 0.05) were shown.
fold increase) was detected in D31.6 cells compared to unsilenced cells, in which a very weak fluorescence signal was observed. To confirm these results, we performed rescue experiments in which D31.6 cells were exposed to recombinant rat PN-1 (rPN-1) [43] . In particular, the treatment for 24 h in the presence of 500 ng/ml rPN-1 led to a significant decrease of the fluorescence intensity (~2.5-fold decrease, p b 0.03) in comparison with untreated D31.6 cells (Fig. 4) . The effect was concentration dependent as at 200 ng/ml rPN-1 since only a moderate reduction of the fluorescence intensity (~1.8-fold decrease at 24 h) was found ( Supplementary Fig. 4 ). These results confirmed that the increase in cell gelatinolytic activity was due to PN-1 silencing.
Therefore, we evaluated whether the PN-1 down-regulation would affect MMP-9 and MMP-2 protein and mRNA expression levels (Fig. 5) . The serum-free conditioned medium collected from control, A7.6 and D31.6 cells were subjected to protein analysis by western blotting (Fig. 5A) and evaluation of the enzyme activity by SDS-PAGE gelatin zymography (Fig. 5B) . Fig. 5A (left panel) showed that in the conditioned medium of unsilenced cells, MMP-9 antibodies revealed an immunoreactive doublet corresponding to pro-MMP-9 (98 kDa) and MMP-9 active form (92 kDa), respectively. The conditioned medium from D31.6 cells showed an increase in MMP-9 protein expression levels (~5.0-fold, p b 0.001) compared to unsilenced ones (set as 1), whereas A7.6 cells only showed a moderate increase (~1.5-fold, p b 0.001). In addition, D31.6 cells showed higher expression levels (~3.5-fold, p b 0.001) of MMP-2 active form (66 kDa) and pro-MMP-2 (72 kDa) whereas A7.6 cells had a pro-MMP-2 expression levels similar to unsilenced cells (Fig. 5A, right panel) . It has to be pointed out that no additional signals at different molecular mass were revealed using these antibodies ( Supplementary Fig. 5 ).
The zymographic pattern (Fig. 5B , left panel) revealed gelatinolytic components at molecular mass ranging from 100 to 80 kDa, expected for MMP-9, and from 72 to 52 kDa for MMP-2. Furthemore, D31.6 cells showed a~5-fold increase (p b 0.001) in gelatinase activity compared to unsilenced cells whereas the conditioned medium from A7.6 cells showed an activity similar (~1.5-fold) to control cells (Fig. 5B, right panel) .
We also determined whether PN-1 down-regulation affects the expression of MMP-9/2 at the transcriptional level using semiquantitative RT-PCR analysis (Fig. 5C ). D31.6 cells exhibited an increase in MMP-9 (~3.2-fold, p b 0.001) and MMP-2 (~2.5-fold, p b 0.001) mRNA expression levels compared to control cells, whereas A7.6 cells had a MMP-9 and MMP-2 mRNA expression levels similar to unsilenced cells. Taken together, these results indicate that PN-1 regulates the expression of MMP-9 and MMP-2 at both transcriptional and translational levels in C6 glioma cells.
Exogenous recombinant PN-1 restores the gelatinolytic activity in PN-1 silenced glioma
To confirm that the down-regulation of endogenous PN-1 levels is responsible for an increased gelatinolytic activity in D31.6 cells, we performed rescue experiments employing exogenous recombinant PN-1 (rPN-1) [43] . To this aim, rPN-1 (200 or 500 ng/ml) was added to the serum-free medium in D31.6 cells and after 48 h, the conditioned medium was subjected to western blotting analysis to evaluate PN-1 protein levels and gel zymography (Fig. 6) . Exogenous recombinant PN-1 was able to abolish the increase in the gelatinase activity observed in the conditioned medium of D31.6 cells (Fig. 6A) . In particular, the exposure to 200 ng/ml rPN-1 induced a strong reduction in MMP-9 gelatinolytic activity (~4-fold, p b 0.001), whereas slight differences were observed in MMP-2 gelatinolytic activity compared to unexposed cells. Moreover, rPN-1 at 500 ng/ml was able to reduce also MMP-2 activity (~3.8-fold, p b 0.001) to the basal level observed in unsilenced cells. The differences observed between MMP-9 and MMP-2 gelatinolytic activities, correlated to the different expression levels reported in Fig. 5 .
In addition, the presence of a PN-1 immunoreactive fragment (~37 kDa) in the conditioned medium of D31.6 cells incubated with 500 ng/ml rPN-1 was found. This fragment can be derived from a proteolytic cleavage by a target protease. To confirm that the increase in gelatinase activity in D31.6 cells was mainly due to MMP-9 and/or MMP-2, selective chemical inhibitors for MMP-9 (Inhibitor I, 100 μM) [28] [6, 29] . PN-1 silencing (right panel), leads to an increase in uPA and MMP-9/2 protein levels, which enhance glioma cell migration and invasiveness through the degradation of ECM components; uPA converts the inactive plasminogen into the active serine protease plasmin which generates active MMP-9/2 from their inactive zymogens [20] . Further, PN-1 might affect MMP-9 transcription by a possible interference with upstream signaling involved in the phosphorylation of Erk1/2 and p38 MAPK [33, 40] .
developing SDS-PAGE zymography (Fig. 6B) . These inhibitors were able to abolish the gelatinase activity thus confirming the identity of MMP-9 and MMP-2 in the zymographic pattern. Taken together, these results confirm that PN-1 silencing enhances MMP-9 and MMP-2 gelatinolytic activity in the conditioned medium from C6 cells.
Selective inhibitors of MMPs or exogenous rPN-1 reduced migration and invasive ability in PN-1 silenced C6 cells
To confirm the role of MMP-9 and MMP-2 in the enhanced cell migration and invasive ability in PN-1 silenced C6 cells, migration and invasion assays were also performed in the presence of MMP-9 Inhibitor I, (25 nM, final concentration) [28] , MMP-2 Inhibitor III (60 nM, final concentration) [46] or rPN-1 (500 ng/ml) [43] which were added to the medium in the upper and lower compartments of the Boyden chambers. The results demonstrated that these inhibitors effectively suppressed the migration ability (Fig. 7A ) and the invasiveness (Fig. 7B ) of D31.6 cells that showed a behavior similar to that of unsilenced ones. In fact, we observed a reduction in the numbers of D31.6 cells that had migrated (~2.8 fold, Fig. 7A ) or invaded (~2.5 fold, Fig. 7B ) in comparison to the untreated D31.6 cells. Conversely, A7.6 cells showed a minimal decrease either in migration or invasion capability. In addition, the exposure to rPN-1 reverted this behavior (Fig. 7C, D) , although to a lower extent compared to MMP inhibitors. These results clearly support the hypothesis that PN-1 affects cell migration and invasive capability through the regulation of MMP-9 and MMP-2 expression levels in C6 glioma cells.
PN-1 silencing stimulates Erk1/2 and p38 MAPK signaling in C6 cells
Previous studies reported that the MAPK family, including Erk and p38, is involved in cancer cell invasion triggered by MMP-9 and MMP-2 [33, 40] . Thus, we investigated whether the enhancement in cell migration and invasiveness mediated by the modulation of MMP-9/2 expression in PN-1 silenced cells, may involve Erk and p38 MAPK signaling pathways. Western blotting analysis (Fig. 8) performed on cell lysates from Ctrl, A7.6 and D31.6 cells, in the presence or in the absence of MMP-9 Inhibitor I (25 nM) [28] and MMP-2 Inhibitor III (60 nM) [46] (Fig. 8A, B) showed that Erk1/2 and p38 phosphorylation levels were significantly increased in D31.6 cells (~2.0 and 2.5-fold, respectively, p b 0.01) compared to unsilenced cells, whereas in A7.6 cells no difference was found. The treatment with either MMP-9 Inhibitor I or MMP-2 Inhibitor III almost completely abolished Erk1/2 and p38 phosphorylation. Furthermore, the treatment of D31.6 cells with rPN-1 (500 ng/ml) [43] (Fig. 8 C, D) also abolished the increase in the phosphorylation of both Erk1/2 and p38 caused by PN-1 silencing. Taken together, these results indicate that the down-regulation of PN-1 may enhance glioma cell migration and invasion via Erk1/2 and p38 pathways in C6 cells.
Discussion
Glioblastoma multiforme (GBM) is the most common and aggressive tumor in CNS with a poor clinical outcome due to the highly invasive potential [34] . The rat C6 glioma cell line [35] , expressing endogenous PN-1 [9] , shows many characteristics of GBM and has been used as an in vitro system model to investigate factors involved in the growth and invasiveness of glioblastoma cells [36, 58] . Because serpins have been proposed to have a protective role against tumor invasion by the inhibition of serine-protease activity, we evaluated the effects of PN-1 silencing on the migration and invasive ability of C6 cells. Our results indicate that the PN-1 down-regulation enhances the migration and invasiveness in stable C6 cells. Notably, D31 cells with a significant reduction in PN-1 expression levels also showed a higher migration and invasive capability (Fig. 2) . These results are in line with data by Xu et al. [29] that demonstrated that prostate cancer cells, PC3-ML over-expressing PN-1, had a reduced invasiveness in matrigel assay therefore indicating that PN-1 may act as a negative regulator of invasive potential in prostate and glioma cells. On the contrary, previous studies indicated that PN-1 exhibits pro-invasive functions in mammary [33] , colorectal [41] , and pancreatic [26] cancer cell lines. Since the invasive ability of tumor cells depends from a critical balance between proteases and their inhibitors in the ECM [14] , PN-1 might interact with proteases or other target molecules depending from the cell micro-environment. Among PN-1 target serine proteases, thrombin and uPA are key enzymes in tissue remodeling [17] [18] [19] that occurs in physiological processes and tumor invasion [16] . In the brain, PN-1 is the main physiological inhibitor of thrombin, a protease involved in the coagulation cascade but also recently known for its role in tumor cell invasion and modulation of MMP expression [17, 58, 61] . However, control and PN-1 silenced C6 cells expressed similar levels of the zymogen prothrombin (72 kDa; Fig. 3A ) whereas enzymatically active thrombin was not detected [62] . Therefore, thrombin inhibition by PN-1 seems to be not involved in the migration and invasiveness of C6 glioma cells, consistent with a previous study in the same cell line [58] . In C6 cells, the down-regulation of PN-1 led to increased uPA protein levels and caseinolytic activity, although no effect was observed at the transcriptional level (Fig. 3C, D) suggesting that PN-1 has little effect on the transcriptional regulation of uPA expression.
PN-1 silencing induced an increase in both cell gelatinolytic activity ( Fig. 4 and Supplementary Fig. 4 ) and MMP-9 expression and gelatinolytic activity, that were significantly enhanced in the culture medium from D31.6, where a more efficient PN-1 down-regulation was achieved (Fig. 5) . Notably, it was also found that PN-1 silencing could up-regulate MMP-2 expression and gelatinolytic activity. Furthermore, these effects were reverted in the presence of selective chemical MMP-9/2 inhibitors as well as by the exposure to exogenous rPN-1. In addition, the migration and invasive potential of D31.6 cells (Fig. 7 ) were restored to the basal level after the exposure to the above-mentioned inhibitors/rPN-1.
These findings are in line with data of Xu et al. [29] and consistent with the hypothesis that in C6 cells, PN-1 significantly prevents cell migration and invasiveness through the regulation of uPA, MMP-9 and MMP-2 expression levels. Furthermore, in C6 cells, MMP-9 may be regulated by PN-1 at transcriptional levels through the activation of Erk1/2 in D31.6 cells (Fig. 8) as well as at post-transcriptional levels; in fact, in ECM PN-1 may become a substrate for MMP-9 [28] .
However, other studies using mammary tumor models [25] and pancreatic cell tumors in mice models [26] have indicated that the over-expression of PN-1 enhanced the invasive potential, whereas the loss of PN-1 causes a decrease in MMP-9 levels [33] . These controversial results on PN-1 functions may be attributable to the different roles played by this serpin depending on the specific cell micro-environment. In fact, since PN-1 is a secreted serpin, its protein levels may affect the biological functions of specific target molecules present in the extracellular environment of C6 glioma cells. In summary, our results suggest that in C6 glioma cells PN-1 exerts an anti-invasive effect through the regulation of uPA level [20] , which induces MMP-9/2 activation in the extracellular environment (Fig. 9, left panel) . The down-regulation of PN-1 endogenous levels led to increased amount of uPA that generates active MMP-9/2 through the activation of plasmin [20] thus enhancing migration and invasive potential of C6 glioma cells (Fig. 9, right panel) . However, the molecular mechanism whereby PN-1 could regulate MMP-9 at the transcriptional level, requires further investigations.
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